phloroglucinol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2153	108-73-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: phloroglucinol phloroglucin phloroglucine 1,3,5-Benzenetriol	A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent. Molecular weight: 126.11 Formula: C6H6O3 CLOGP: 0.14 LIPINSKI: 0 HAC: 3 HDO: 3 TPSA: 60.69 ALOGS: -0.55 ROTB: 0

Molecule

Description

Molfile Inchi Smiles

Synonyms:

phloroglucinol
phloroglucin
phloroglucine
1,3,5-Benzenetriol

A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.

Molecular weight: 126.11
Formula: C6H6O3
CLOGP: 0.14
LIPINSKI: 0
HAC: 3
HDO: 3
TPSA: 60.69
ALOGS: -0.55
ROTB: 0

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	113.39	36.50	44	2353	33792	63452833
Hepatocellular injury	107.58	36.50	40	2357	27341	63459284
Acute kidney injury	58.31	36.50	60	2337	263355	63223270
Cell death	55.58	36.50	14	2383	2587	63484038
Hyponatraemia	54.41	36.50	40	2357	111860	63374765
Cholestasis	54.07	36.50	25	2372	29409	63457216
Thrombocytopenia	45.82	36.50	41	2356	151116	63335509
Febrile bone marrow aplasia	41.26	36.50	14	2383	7311	63479314
Poisoning deliberate	38.98	36.50	15	2382	11203	63475422
Hepatosplenic candidiasis	38.72	36.50	7	2390	264	63486361

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperleukocytosis	65.57	30.53	16	1709	1986	34953220
Urethral valves	62.29	30.53	11	1714	275	34954931
Pancreatitis acute	60.74	30.53	29	1696	28112	34927094
Febrile bone marrow aplasia	47.01	30.53	17	1708	8192	34947014
Acute kidney injury	41.48	30.53	62	1663	304926	34650280
Puncture site haematoma	40.67	30.53	7	1718	150	34955056
Bicytopenia	39.07	30.53	11	1714	2373	34952833
Diarrhoea infectious	36.88	30.53	8	1717	589	34954617
Tuberculosis	35.46	30.53	14	1711	8563	34946643
Eosinophilia	30.76	30.53	18	1707	26204	34929002

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	119.08	29.26	55	4037	47538	79692758
Drug reaction with eosinophilia and systemic symptoms	111.98	29.26	58	4034	64186	79676110
Acute kidney injury	91.36	29.26	122	3970	519282	79221014
Pancreatitis acute	84.15	29.26	44	4048	49560	79690736
Febrile bone marrow aplasia	77.35	29.26	28	4064	12992	79727304
Cholestasis	68.36	29.26	39	4053	52070	79688226
Hyperleukocytosis	65.51	29.26	17	4075	2593	79737703
Thrombocytopenia	55.36	29.26	68	4024	265191	79475105
Cell death	51.39	29.26	16	4076	4683	79735613
Toxic skin eruption	50.25	29.26	24	4068	22269	79718027
Eosinophilia	41.59	29.26	27	4065	45318	79694978
Abdominal pain	40.59	29.26	72	4020	389497	79350799
Puncture site haematoma	39.24	29.26	7	4085	178	79740118
Hypokalaemia	38.51	29.26	42	4050	143998	79596298
Drug ineffective	36.42	29.26	6	4086	1080907	78659389
Hyponatraemia	36.08	29.26	45	4047	177803	79562493
Hepatic cytolysis	34.72	29.26	20	4072	27131	79713165
Wrong product administered	34.23	29.26	14	4078	8998	79731298
Acute generalised exanthematous pustulosis	34.15	29.26	17	4075	17237	79723059
Neutropenia	33.63	29.26	56	4036	287654	79452642
Poisoning deliberate	32.75	29.26	17	4075	18811	79721485
Gamma-glutamyltransferase increased	32.55	29.26	25	4067	54655	79685641
Porphyria	32.01	29.26	6	4086	202	79740094
Fatigue	31.65	29.26	5	4087	929722	78810574
Bicytopenia	31.35	29.26	11	4081	4659	79735637
Hepatosplenic candidiasis	31.16	29.26	7	4085	581	79739715
Rash maculo-papular	29.84	29.26	24	4068	56054	79684242

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A03AX12	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS Other drugs for functional gastrointestinal disorders
MeSH PA	D007202	Indicators and Reagents
CHEBI has role	CHEBI:84735	algal metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.35	acidic
pKa2	10.35	acidic
pKa3	12.36	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-secretase 1	Enzyme	P56817	BACE1_HUMAN		IC50	4.44		CHEMBL

External reference:

ID	Source
N0000166595	NUI
D00152	KEGG_DRUG
C0031566	UMLSCUI
CHEBI:16204	CHEBI
13X	PDB_CHEM_ID
CHEMBL473159	ChEMBL_ID
359	PUBCHEM_CID
DB12944	DRUGBANK_ID
D010696	MESH_DESCRIPTOR_UI
DHD7FFG6YS	UNII
8196	RXNORM
005931	NDDF
19341000122103	SNOMEDCT_US

Pharmaceutical products:

None